Skip to main content

Healthy Men

14
Pipeline Programs
8
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
12
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
1 program
1
ezetimibePhase 4
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
ezetimibePhase 41 trial
Active Trials
NCT00317993Completed60Est. Jul 2004
Human BioSciences
Human BioSciencesWV - Martinsburg
3 programs
2
Dimethandrolone UndecanoatePhase 1
Nestorone + Testosterone Combination GelPhase 1
ControlN/A1 trial
Active Trials
NCT01293591Completed18Est. Aug 2010
Innovation Pharmaceuticals
3 programs
3
Dimethandrolone UndecanoatePhase 11 trial
Dimethandrolone UndecanoatePhase 11 trial
Nestorone + Testosterone Combination GelPhase 11 trial
Active Trials
NCT01382069Completed100Est. May 2017
NCT02927210Completed106Est. Apr 2025
NCT02994602Completed26Est. Oct 2017
Biocorp
BiocorpFrance - Issoire
2 programs
2
BAT1706 InjectionPhase 11 trial
BAT1806 prefilled subcutaneous injection/RoActemra®Phase 11 trial
Active Trials
NCT05865574Unknown38Est. Jan 2024
NCT05968508Completed300Est. Oct 2024
Bio-Thera Solutions
Bio-Thera SolutionsChina - Guangzhou
2 programs
2
BAT1706 InjectionPhase 1
BAT1806 prefilled subcutaneous injection/RoActemra®Phase 1
Lundbeck
LundbeckDenmark - Copenhagen
2 programs
2
Part A: Lu AF35700Phase 11 trial
Vortioxetine 10 mgPhase 11 trial
Active Trials
NCT02093169Completed12
NCT02072278Completed32
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD8329Phase 11 trial
Active Trials
NCT00935662Completed119Est. Aug 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sharp Therapeuticsezetimibe
BiocorpBAT1806 prefilled subcutaneous injection/RoActemra®
BiocorpBAT1706 Injection
Innovation PharmaceuticalsDimethandrolone Undecanoate
Innovation PharmaceuticalsNestorone + Testosterone Combination Gel
LundbeckVortioxetine 10 mg
LundbeckPart A: Lu AF35700
Innovation PharmaceuticalsDimethandrolone Undecanoate
AstraZenecaAZD8329
Human BioSciencesControl

Clinical Trials (10)

Total enrollment: 811 patients across 10 trials

NCT00317993Sharp Therapeuticsezetimibe

LDL Receptor Under Ezetimibe and Simvastatin

Start: Apr 2004Est. completion: Jul 200460 patients
Phase 4Completed
NCT05968508BiocorpBAT1806 prefilled subcutaneous injection/RoActemra®

A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects

Start: Aug 2023Est. completion: Oct 2024300 patients
Phase 1Completed
NCT05865574BiocorpBAT1706 Injection

A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection

Start: Jun 2023Est. completion: Jan 202438 patients
Phase 1Unknown
NCT02927210Innovation PharmaceuticalsDimethandrolone Undecanoate

Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)

Start: Feb 2017Est. completion: Apr 2025106 patients
Phase 1Completed
NCT02994602Innovation PharmaceuticalsNestorone + Testosterone Combination Gel

Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males

Start: Jan 2017Est. completion: Oct 201726 patients
Phase 1Completed
NCT02072278LundbeckVortioxetine 10 mg

Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects

Start: Feb 201432 patients
Phase 1Completed
NCT02093169LundbeckPart A: Lu AF35700

D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound

Start: Feb 201412 patients
Phase 1Completed
NCT01382069Innovation PharmaceuticalsDimethandrolone Undecanoate

Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men

Start: Mar 2012Est. completion: May 2017100 patients
Phase 1Completed
NCT00935662AstraZenecaAZD8329

A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses

Start: Jul 2009Est. completion: Aug 2010119 patients
Phase 1Completed
NCT01293591Human BioSciencesControl

Garlic Intake And Biomarkers Of Cancer Risk

Start: Jul 2010Est. completion: Aug 201018 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.